2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1 ‐mutated acute myeloid leukaemia

(2021) Sanam Loghavi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)

(2021) Nikhil Patkar et al.   LEUKEMIA

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial

(2021) Catia Simoes et al.   Blood Advances

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

(2021) Bob Löwenberg et al.   Blood Advances

Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations

(2021) Roland B. Walter et al.   LEUKEMIA

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively

(2021) Maël Heiblig et al.   Cancers

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

(2021) Abhishek Maiti et al.   Blood Advances

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

(2021) Michael Heuser et al.   Blood Advances

Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML

(2021) Cheng-Hong Tsai et al.   Blood Advances

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration

(2021) Luca Vincenzo Cappelli et al.   LEUKEMIA

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

(2021) Ing S. Tiong et al.   Blood Advances

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

(2020) Richard Dillon et al.   BLOOD

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia

(2020) Robert Puckrin et al.   HAEMATOLOGICA

Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

(2020) Adriano Venditti et al.   LEUKEMIA

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

(2020) Robert P. Hasserjian et al.   BLOOD

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting

(2020) Diana Hanekamp et al.   BRITISH JOURNAL OF HAEMATOLOGY

Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting

(2020) Katharina M. Lang et al.   Trials

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)

(2020) Andreas Burchert et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial

(2020) Silke Kapp-Schwoerer et al.   BLOOD

Acute Myeloid Leukemia Measurable Residual Disease Detection by Flow Cytometry in Peripheral Blood Versus Bone Marrow

(2020) Colin Douglas Godwin et al.   BLOOD

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

(2020) Nicholas J. Short et al.   JAMA Oncology

Germline mutations in MDS/AML predisposition disorders

(2020) Lucy A. Godley   CURRENT OPINION IN HEMATOLOGY

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

(2020) Charles Craddock et al.   JOURNAL OF CLINICAL ONCOLOGY

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses

(2020) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation

(2020) Tanzhen Wang et al.   LEUKEMIA & LYMPHOMA

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells

(2020) Diana Hanekamp et al.   BLOOD

Pre-analytical processes in medical diagnostics: new regulatory requirements and standards

(2019) Georges Dagher et al.   New Biotechnology

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

(2019) Sibylle Cocciardi et al.   Nature Communications

Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5‐azacytidine: Identification of responding patients

(2019) Marta Santaliestra et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

(2019) Adriano Venditti et al.   BLOOD

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group

(2019) Frank G. Rücker et al.   BLOOD

Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes

(2019) Anna Elinder Camburn et al.   PATHOLOGY

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

(2019) Veit Bücklein et al.   BLOOD

An R‐Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data

(2019) Francis Lacombe et al.   CYTOMETRY PART A

Leukemia‐associated immunophenotypes subdivided in “categories of specificity” improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia

(2019) Giovanni Rossi et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing

(2019) Vidya Balagopal et al.   PLoS One

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemia

(2019) Jack Ghannam et al.   BRITISH JOURNAL OF HAEMATOLOGY

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

(2019) Christopher S. Hourigan et al.   JOURNAL OF CLINICAL ONCOLOGY

Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes

(2019) Diana Hanekamp et al.   PATHOLOGY

Minimal residual disease and stem cell transplantation outcomes

(2019) Jacqueline Cloos et al.   Hematology-American Society of Hematology Education Program

Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu

(2018) Maria H Gilleece et al.   AMERICAN JOURNAL OF HEMATOLOGY

Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

(2018) Takaaki Konuma et al.   ANNALS OF HEMATOLOGY

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies

(2018) Robert L. Bowman et al.   Cell Stem Cell

ICCS/ESCCA Consensus Guidelines to detect GPI-deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 3 - Data Analysis, Reporting and Case Studies

(2018) Andrea Illingworth et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

(2018) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

(2018) Felicitas Thol et al.   BLOOD

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia

(2018) Laura W. Dillon et al.   HAEMATOLOGICA

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT

(2018) Christoph Schmid et al.   BRITISH JOURNAL OF HAEMATOLOGY

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

(2018) Uwe Platzbecker et al.   LANCET ONCOLOGY

CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

(2018) Wendelien Zeijlemaker et al.   LEUKEMIA

Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia

(2017) Francis Lacombe et al.   HEMATOLOGICAL ONCOLOGY

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group

(2017) Marie Balsat et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML

(2017) S Herold et al.   LEUKEMIA

Measurable residual disease testing in acute myeloid leukaemia

(2017) C S Hourigan et al.   LEUKEMIA

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

(2017) J Flores-Montero et al.   LEUKEMIA

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia

(2017) Adriana Plesa et al.   World Journal of Stem Cells

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

(2016) Yasmin Abaza et al.   BLOOD

Harmonemia: a universal strategy for flow cytometry immunophenotyping—A European LeukemiaNet WP10 study

(2016) F Lacombe et al.   LEUKEMIA

Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia

(2016) Y Zhou et al.   LEUKEMIA

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry

(2015) Sergio Matarraz et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

(2015) Juliette Lambert et al.   Oncotarget

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia

(2014) T. Prebet et al.   HAEMATOLOGICA

Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia

(2014) Monique Terwijn et al.   PLoS One

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

(2013) N. Shayegi et al.   BLOOD

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part I - rationale and aims

(2013) Bruce H. Davis et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part V - assay performance criteria

(2013) Brent Wood et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Technical issues: flow cytometry and rare event analysis

(2013) B. D. Hedley et al.   International Journal of Laboratory Hematology

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

(2013) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

(2013) Monique Terwijn et al.   JOURNAL OF CLINICAL ONCOLOGY

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

(2010) F. Lo-Coco et al.   BLOOD

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY